For Healthcare Professionals

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

clipboard-pencil

About the study

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Diagnosis of MS according to the 2017 Revised McDonald criteria
  2. Relapsing MS: relapsing forms of MS (RMS) including RMS and secondary progressive MS (SPMS)
  3. Disability status at screening defined by Expanded Disability Status Scale (EDSS) score of 0 to 4 (inclusive)
  4. MS treatment history with a maximum of 3 Disease Modifying Therapies (DMTs), where all fumarates are considered as one DMT
  5. Subject transitioning from either any fumarate-based RMS approved therapies, such as dimethyl fumarate (DMF) or diroximel fumarate (DRF), or fingolimod which was administered for a period of at least 6 months, as their last DMT before first study drug administration
  6. Breakthrough disease activity while the participant was adequately using fumarates or fingolimod prior to transitioning for a minimum of 6 months as evidenced by one or more clinically reported relapses or one or more signs of Magnetic Resonance Imaging (MRI) activity (e.g. Gd+ enhancement, new or enlarging T2 lesions)
  7. Neurologically stable within one month prior to first study drug administration

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Subjects with primary progressive MS or SPMS without disease activity
  2. Subjects meeting criteria for neuromyelitis optica
  3. Disease duration of more than 10 years since diagnosis
  4. Pregnant or nursing (lactating) women
  5. Women of child-bearing potential unless they are using highly effective forms of contraception during dosing and for at least 6 months after stopping study medication
  6. Subjects with active chronic disease of the immune system other than MS or with immunodeficiency syndrome
  7. Subjects with active systemic bacterial, fungal or viral infections (such as hepatitis, HIV, COVID-19), or known to have Acquired Immunodeficiency Syndrome (AIDS)
  8. Subjects with neurological symptoms consistent with Progressive Multifocal Leukoencephalopathy (PML) or with confirmed PML
  9. Subjects at risk of developing or having reactivation of syphilis or tuberculosis (e.g. subjects with known exposure to, or history of syphilis, or active or latent tuberculosis, even if previously treated), as confirmed by medical history or per local practice
  10. Subjects with active hepatitis B and C disease, assessed locally
  11. Have received any live or live-attenuated vaccines within 4 weeks prior to first study drug administration
  12. Have been treated with medications as specified or within timeframes specified (e.g. corticosteroids, ofatumumab, rituximab, ocrelizumab, alemtuzumab, natalizumab, daclizumab, cyclophosphamide, teriflunomide etc.)
  13. Subjects suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the investigator

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Relapsing Multiple Sclerosis

Age (in years)

18 - 60

Phase

Phase 3

Participants needed

564

Est. Completion Date

Apr 11, 2025

Treatment type

Interventional


Sponsor

Novartis

ClinicalTrials.gov identifier

NCT04353492

Study number

COMB157G23101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.